entertainment -WSS

entertainment

author：hotspot 2025-09-27 23:03:06 - browse：32

Hyacinth Empinado/STAT

The body mass index, or BMI, is the formula that’s used most often to diagnose overweight and obesity. But unlike other common diagnoses, there is a certain stigma applied to people with a high body mass index, or BMI, which can affect how they are perceived by peers, providers, and society at large.

Despite the ubiquity of the BMI in medicine, many argue that it is a flawed tool, with a strange history. In recent months, the BMI has become more relevant than ever as the new semaglutide weight loss drugs are poised to change how obesity is understood and treated.

BMI is a simple calculation — a person’s weight in kilograms divided by the square of their height. But how BMI is then translated into a diagnosis is complicated and flawed.

Related: New weight loss drugs are changing the narrative on obesity, with a push from pharma

Watch this video to learn more about the history of the BMI — how it became so entrenched in medicine and, surprisingly, how its introduction may have set back decades of work on how obesity contributes to disease.

A STAT series is examining new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about The Obesity Revolution.

Previous article： Alkermes shareholders re
Next article： A protest over insulin prices is seen as a fight for life

WSS

Syphilis numbers in the United States reach record heights

10 reasons why health care startups fail

Global cancer cases to surge 77% by 2050, WHO report says

Why Novartis is going to walk from its acquisition of MorphoSys

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

entertainment

Related: New weight loss drugs are changing the narrative on obesity, with a push from pharma

focus

Walensky prepares to leave CDC — and Congress — behind

Why Novartis is going to walk from its acquisition of MorphoSys

Guidelines to prevent youth baseball injuries need more muscle

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Boston competes with Raleigh

Moonlake's readout produced a cash windfall. Risks remain

Gene therapy for Afghan refugees’ infant will be fully covered

BioMarin wins approval for gene therapy to treat hemophilia A

Padmanee Sharma of MD Anderson at center of lawsuit over credit

entertainment

How generative AI ratchets up security threats for health systems

340B reform proposal comes out of Senate working group

Bernie Sanders is gearing up to subpoena pharma CEOs

Devoted Health’s losses in Medicare Advantage persist

The CDC's new social media misinformation war

Why CTE doesn’t keep Americans from enjoying the Super Bowl

leisure time

focus

leisure time

hotspot